Prevalence of elevated LDL-cholesterol and the risk of cardiovascular events in a population with established atherosclerotic cardiovascular disease, type 2 diabetes and metabolic dyslipidemia

被引：0
|
作者：
Rana, J. [1 ]
Liu, J. Y. [2 ]
Moffet, H. H. [2 ]
Boklage, S. H. [3 ]
Mallya, U. S. [4 ]
Karter, A. J. [2 ]
机构：
[1] Kaiser Permanente Northern Calif, Div Cardiol, Oakland, CA USA
[2] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA
[3] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[4] Sanofi US, Bridgewater, MA USA
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1715
引用
收藏
页码：345 / 345
页数：1
相关论文
共 50 条
  • [1] Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease
    Rana, Jamal S.
    Liu, Jennifer Y.
    Moffet, Howard H.
    Sanchez, Robert J.
    Khan, Irfan
    Karter, Andrew J.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2020, 133 (02): : 200 - 206
  • [2] LDL-CHOLESTEROL AND CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES MELLITUS TYPE 2
    Tudor, C.
    Iana, A.
    Jeberean, R. A.
    Petrus, A.
    Buzas, R.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 33 - 34
  • [3] LDL-CHOLESTEROL CORRECTED FOR LP(A)-CHOLESTEROL, RISK THRESHOLDS AND CARDIOVASCULAR EVENTS
    Willeit, P.
    Yeang, C.
    Moriarty, P. M.
    Tschiderer, L.
    Varvel, S. A.
    Mcconnell, J. P.
    Tsimikas, S.
    [J]. ATHEROSCLEROSIS, 2020, 315 : E34 - E35
  • [4] METABOLIC DYSLIPIDEMIA AND RISK OF CORONARY HEART DISEASE IN ADULTS WITH DIABETES AND LOW LDL-CHOLESTEROL
    Rana, Jamal S.
    Liu, Jennifer Y.
    Moffet, Howard H.
    Solomon, Matthew
    Go, Alan S.
    Jaffe, Marc
    Karter, Andrew J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1341 - A1341
  • [5] LDL-Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk
    Ofori-Asenso, Richard
    Zoungas, Sophia
    Tonkin, Andrew
    Liew, Danny
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (02) : 235 - 238
  • [6] LDL-Cholesterol and Atherosclerotic Cardiovascular Disease Innocent Bystander or Essential Ingredient
    Egom, Emmanuel E.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (06) : 705 - 706
  • [7] REPLY: LDL-Cholesterol and Atherosclerotic Cardiovascular Disease Innocent Bystander or Essential Ingredient?
    Pastori, Daniele
    Nocella, Cristina
    Farcomeni, Alessio
    Bartimoccia, Simona
    Carnevale, Roberto
    Violi, Francesco
    Pignatelli, Pasquale
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (06) : 706 - 707
  • [8] Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment
    Carr, Stuart S.
    Hooper, Amanda J.
    Sullivan, David R.
    Burnett, John R.
    [J]. PATHOLOGY, 2019, 51 (02) : 148 - 154
  • [9] Metabolic syndrome in the Philippine general population: prevalence and risk for atherosclerotic cardiovascular disease and diabetes mellitus
    Morales, Dante D.
    Punzalan, Felix Eduardo R.
    Paz-Pacheco, Elizabeth
    Sy, Rody G.
    Duante, Charmaine A.
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2008, 5 (01): : 36 - 43
  • [10] Elevated Lipoprotein(a) prevalence and association with family history of premature cardiovascular disease in general population with moderate cardiovascular risk and increased LDL cholesterol
    Gulayin, Pablo E.
    Lozada, Alfredo
    Schreier, Laura
    Gutierrez, Laura
    Lopez, Graciela
    Poggio, Rosana
    Mores, Nora
    Ponzo, Jacqueline
    Calandrelli, Matias
    Lanas, Fernando
    Irazola, Vilma
    [J]. IJC HEART & VASCULATURE, 2022, 42
12345